Is INO a buy or sell?
For example, a stock trading at $35 with earnings of $3 would have an earnings yield of 0.0857 or 8.57%. A yield of 8.57% also means 8.57 cents of earnings for $1 of investment….Momentum Scorecard. More Info.
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 24.75% |
| 2 | Buy | 18.15% |
| 3 | Hold | 9.70% |
| 4 | Sell | 5.35% |
Why is INO stock dropping?
Stock Market Plunge: 2 Stocks to Avoid Right Now Inovio Pharmaceuticals encountered a series of headwinds in its quest to market its experimental coronavirus vaccine, INO-4800. Recently, the company discontinued a phase 3 clinical study for this candidate.
What is the future of INO stock?
Stock Price Forecast The 3 analysts offering 12-month price forecasts for Inovio Pharmaceuticals Inc have a median target of 3.00, with a high estimate of 8.00 and a low estimate of 2.00. The median estimate represents a +39.21% increase from the last price of 2.15.
Is it good to invest INO?
21, INO stock has a Composite Rating of 19 out of a best-possible 99. The Composite Rating is a 1-99 measure of a stock’s key fundamental and technical growth measures. This means Inovio stock outranks 19% of all stocks in terms of that metric. In 2020, the biotech lost $1.07 per share on $7.4 million in sales.
Is inovio undervalued?
The current market capitalization of $850 million includes some assumption of success, but since I expect VGX-3100 revenue to top $250 million annually at some point, in my view Inovio is currently undervalued.
Is inovio a good company?
Is Inovio Biomedical a good company to work for? Inovio Biomedical has an overall rating of 3.4 out of 5, based on over 35 reviews left anonymously by employees. 58% of employees would recommend working at Inovio Biomedical to a friend and 37% have a positive outlook for the business.
What is Ino price target?
Stock Price Target INO
| High | $8.00 |
|---|---|
| Median | $2.50 |
| Low | $1.00 |
| Average | $3.50 |
| Current Price | $1.51 |
What is the long range forecast for INO stock?
Inovio Pharmaceuticals Inc quote is equal to 1.765 USD at 2022-06-04. Based on our forecasts, a long-term increase is expected, the “INO” stock price prognosis for 2027-05-26 is 5.026 USD. With a 5-year investment, the revenue is expected to be around +184.73%. Your current $100 investment may be up to $284.73 in 2027.
Does inovio have a Covid vaccine?
INOVIO scientists are coronavirus experts. INOVIO was the first to advance its DNA vaccine INO-4700 against MERS CoV, a related coronavirus, into evaluation in humans.
What is the target price for Ino?
Stock Price Target INO
| High | $8.00 |
|---|---|
| Median | $3.00 |
| Low | $2.00 |
| Average | $4.33 |
| Current Price | $2.17 |
How effective is Inovio vaccine?
INOVIO IS A LEADER IN CORONAVIRUS DNA In a recently published paper in Lancet Infectious Diseases, INOVIO’s Phase 1 study of its MERS-CoV vaccine demonstrated it was well tolerated and furthermore induced high levels of antibody responses in roughly 95% of study participants.
Who founded Inovio Pharmaceuticals?
J. Joseph Kim
Also in development are Phase 2 immuno-oncology programs targeting head and neck cancer, bladder cancer, and glioblastoma, as well as platform development programs in hepatitis B, Zika, Ebola, MERS, and HIV. Inovio was co-founded by President, CEO, and Direc- tor, J. Joseph Kim, Ph. D, and David B.
Is inovio working on a Covid vaccine?
As Inovio moves forward, the company intends to expand its partnership with Advaccine beyond INO-4800 to include heterologous boosters and vaccine candidates covering future COVID-19 variants.
Is inovio an American company?
Inovio Pharmaceuticals is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases.
When did inovio go public?
Dec. 8, 1998
You could have purchased shares of what would later be known as Inovio on Dec. 8, 1998, for a split-adjusted price of $60 per share.
How effective is INOVIO vaccine?
Does INOVIO have a vaccine?
The vaccine candidate is an intradermally-injected DNA plasmid vaccine designed to control the virological spread of COVID-19. In its announcement, changes in infection rates across the globe indicate the company will need to increase the trial size and cost of the INNOVATE study.
Who owns Inovio Pharmaceuticals?
Top 10 Owners of Inovio Pharmaceuticals Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| SSgA Funds Management, Inc. | 10.16% | 23,267,928 |
| BlackRock Fund Advisors | 6.74% | 15,433,492 |
| The Vanguard Group, Inc. | 4.77% | 10,917,466 |
| D. E. Shaw & Co. LP | 2.40% | 5,499,823 |
Is INOVIO working on a COVID vaccine?
How many shares of Inovio are there?
Share Statistics
| Avg Vol (3 month) 3 | 5.84M |
|---|---|
| Shares Outstanding 5 | 229.04M |
| Implied Shares Outstanding 6 | N/A |
| Float 8 | 225.14M |
| % Held by Insiders 1 | 1.66% |